Immune Regulation: changing the course of disease

PIN201104 (‘1104) clinical impact

Asthma is a common chronic disease that is estimated to affect as many as 339 million people worldwide.10

Globally, asthma is ranked 16th among the leading causes of years lived with disability and 28th among the leading causes of burden of disease, as measured by disability adjusted life years (DALYs).

Annual direct costs of asthma are more than US$3,000 per patient in the US 10, rising to $100,000 in patients with severe disease, and prevalence of asthma in North America is up to 8% of adults.11,12 Reliable national estimates of costs are not available for the vast majority of developing countries, however prevalence among adults is known to be up to 7% in Latin America13 and up to 10% in Asia.14


Only 30% of individuals diagnosed with asthma receive optimised treatment, and only a small fraction of patients is compliant with care.

Kevin Holton, Head of Respiratory Programme, UK Department of Health, at ERS 2013


Despite great strides in treatment, there remains a very real clinical need for a treatment for moderate-to-severe asthma which is effective, convenient and affordable:

‘1104 is likely to enter the market in moderate-to-severe asthma:

Immune Regulation: changing the course of disease

At Immune Regulation our aim is to deliver a treatment that is both effective and convenient to enable patients with asthma to live a normal life without regular hospitalisation or daily medication, no matter what triggers their attacks.

Although ‘1104 has primarily been assessed preclinically in asthma models, it may also be effective in atopic dermatitis, COPD, and inflammatory bowel diseases.

With ‘1104, Immune Regulation may offer a new paradigm for treatment of asthma and other immune diseases